Healthcare / Medical Instruments & SuppliesNasdaqGM
$29.55
-0.34 (-1.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-40.0M · quality 33.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.4%
↓Gross Margin
76.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2026 · 16 años de histórico normalizado
Revenue CAGR
+9.6%
FCF CAGR
—
FCF margin
-16.7%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $239.4M · net income $-80.4M · FCF $-40.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $239.4M | $239.4M | $239.4M | $313.9M | $322.4M | $284.4M | $230.5M | $20.9M | $22.9M | $22.3M | $23.3M | $75.0M | $72.2M | $63.8M | $62.8M | $55.0M |
| Net Income | $-80.4M | $-80.4M | $-80.4M | $-20.2M | $21.3M | $39.7M | $27.5M | $14.0M | $5.0M | $-2.1M | $-12.1M | $-8.4M | $398000.00 | $-1.8M | $1.3M | $53000.00 |
| EBITDA | — | — | $-37.2M | $-5.7M | $33.2M | $48.3M | — | — | — | — | — | — | — | — | — | — |
| EPS | -1.62 | -1.62 | -1.62 | -0.41 | 0.43 | 0.79 | 0.56 | 0.30 | 0.11 | -0.05 | -0.30 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 |
| Gross Margin | 76.2% | 76.2% | 76.2% | 76.3% | 78.4% | 78.5% | 77.5% | 536.6% | 400.1% | 288.4% | 250.3% | 65.1% | 69.7% | 69.4% | 67.5% | 63.8% |
| Operating Margin | -38.3% | -38.3% | -19.2% | -4.0% | 8.7% | 15.4% | 14.5% | 56.8% | 28.8% | -16.3% | -54.3% | -10.7% | 1.0% | -1.9% | 4.4% | -4.7% |
| Net Margin | -33.6% | -33.6% | -33.6% | -6.4% | 6.6% | 13.9% | 11.9% | 67.3% | 21.7% | -9.6% | -52.0% | -11.2% | 0.6% | -2.8% | 2.1% | 0.1% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | 0.11 | 0.10 | 0.09 | 0.09 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | — | — | 5.12 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-40.0M | $-40.0M | $-40.0M | $-7.7M | $-3.6M | $17.6M | $30.3M | $15.7M | $10.5M | $1.8M | $-2.2M | — | — | $946000.00 | $4.4M | $-4.7M |
| Returns | ||||||||||||||||
| ROE | -23.4% | -23.4% | -23.4% | -5.1% | 5.5% | 11.8% | 10.5% | 8.8% | 3.8% | -5.0% | -32.0% | -22.6% | 1.0% | -5.6% | 4.6% | 0.2% |
| Valuation | ||||||||||||||||
| P/E | — | — | — | — | 66.19 | 76.00 | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 37.91 | 60.22 | — | — | — | — | — | — | — | — | — | — |
| P/B | — | — | 4.26 | 3.03 | 3.64 | 8.82 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -23.7% | -23.7% | -23.7% | -2.6% | 13.4% | — | 1004.7% | -8.8% | 2.6% | -4.4% | -68.9% | 3.8% | 13.2% | 1.6% | 14.2% | — |
| EPS Growth | -295.1% | -295.1% | -295.1% | -195.3% | -45.6% | — | 86.7% | 172.7% | 320.0% | 83.3% | -36.4% | -2300.0% | 120.0% | -225.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.62 → -1.62
Residual
+65.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.